Raf
Raf is a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes.
Products for Raf
- Cat.No. Product Name Information
- GC32797 AD80 AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
-
GC15055
AZ 628
Raf kinases,potent and ATP-competitive
-
GC19479
AZ304
A dual inhibitor
- GC10534 B-Raf IN 1 B-Raf inhibitor
- GC65978 B-Raf IN 10 B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activity.
- GC67800 B-Raf IN 11
- GC64550 B-Raf IN 2 B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer.
- GC12151 B-Raf inhibitor
- GC11599 B-Raf inhibitor 1 B-Raf inhibitor 1 is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively.
- GC14907 B-Raf inhibitor 1 dihydrochloride B-B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively.
- GC32950 Belvarafenib An inhibitor of B-RAF and C-RAF
- GC35488 Belvarafenib TFA Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
- GC19066 BGB-283 BGB-283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
- GC18178 BI-882370 A RAF inhibitor
- GC13468 BI-D1870 P90 RSK inhibitor,ATP-competitive and cell-permeable
- GC11497 BIRB 796 (Doramapimod) BIRB 796 (Doramapimod) (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM.
- GC12482 BRAF inhibitor
- GC19091 CCT196969 CCT196969, a pan-Raf inhibitor, inhibits B-Raf with an IC50 of 0.1 uM.
- GC16845 CEP-32496 CEP-32496 (CEP-32496; RXDX-105) is a highly potent and orally efficacious inhibitor of BRAFV600E with a Kd of 14 nM.
- GC17860 CEP-32496 hydrochloride A potent inhibitor of B-Raf
- GC15187 Dabrafenib (GSK2118436) Dabrafenib (GSK2118436) (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively.
- GC12486 Dabrafenib Mesylate (GSK-2118436) A Raf kinase inhibitor
- GC33206 ERK-IN-1 ERK-IN-1 (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. ERK-IN-1 hydrochloride can also inhibit RAF.
- GC67964 Exarafenib
- GC10505 GDC-0879 B-Raf inhibitor,potent and selective
- GC65949 GNE-9815 GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for CRAF and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers.
- GC11685 GW5074 C-Raf inhibitor,potent and selective
- GC36223 HG6-64-1 HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1); has a IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells.
- GC15924 L-779,450 Raf kinase inhibitor
- GC16576 LGX818 LGX818 (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).
-
GC19507
LUT-014
LUT014 is a topical B-Raf Inhibitor
- GC19228 LXH254 LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A.
-
GC13980
LY3009120
LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.
- GC15296 ML 786 dihydrochloride Raf kinase inhibitor
- GC11649 MLN 2480 An oral pan-Raf kinase inhibitor
- GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib
- GC15821 PF-04880594 RAF inhibitor
- GC14732 PLX-4720 An orally-available inhibitor of the B-raf mutant B-RafV600E
- GC62206 PLX-4720-d7 PLX-4720-d7 is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC50?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
- GC10324 PLX7904 paradox-breaker RAF inhibitor, potent and selective
- GC64828 PLX7922 PLX7922, a RAF inhibitor, can bind with BRAFV600E. PLX7922 inhibits pERK in BRAFV600E cell lines, and activates pERK in mutant NRAS cell lines.
- GC32686 PLX8394
- GC65479 PROTAC B-Raf degrader 1 PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf based on Cereblon ligand with anti-cancer activity.
- GC61485 Raf inhibitor 2 Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research.
- GC37068 RAF mutant-IN-1 RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively.
- GC15818 RAF265 Multiple intracellular kinases inhibitor
- GC19307 RAF709 RAF709 is a novel Raf kinase inhibitor extracted from patent WO2014151616A1, compound example 131, has an IC50 of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.
- GC62504 RAS/RAS-RAF-IN-1 RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity.
- GC14606 Regorafenib hydrochloride A multi-kinase inhibitor
- GC14534 Regorafenib monohydrate A multi-kinase inhibitor
- GC62448 Rineterkib hydrochloride Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
- GC12406 RO5126766(CH5126766) RO5126766(CH5126766) (CH5126766) is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAFV600E, CRAF, MEK, and BRAF (IC50: 8.2, 56, 160 nM, and 190 nM, respectively).
- GC62269 RRD-251 RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities.
- GC11890 SB590885 Potent B-Raf inhibitor
-
GC17369
Sorafenib
Sorafenib acts as a multi-kinase inhibitor, targeting Raf-1 and B-Raf with IC50 values of 6 nM and 22 nM, respectively.
- GC37664 Sorafenib (D3) An internal standard for the quantification of sorafenib
- GC37665 Sorafenib (D4) Sorafenib (D4) (Bay 43-9006-d4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
- GC49700 Takeda-6d
- GC68350 Tinlorafenib
-
GC13412
Vemurafenib (PLX4032, RG7204)
An inhibitor of mutant V600E and wild type B-Raf
- GC13286 ZM336372 C-Raf inhibitor, potent and selective